Notice of Results

Sareum Holdings PLC
04 February 2008


For immediate release                                       4 February 2008



                              SAREUM HOLDINGS PLC
                          ("Sareum" or the "Company")

                           Notice of Interim Results



Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business, will announce its Interim Results for the six months ended 31 December
2007 on Thursday 6 March 2008.



An analyst presentation will take place on the day at 10:00 am at Buchanan
Communications, 45 Moorfields, London EC2Y 9AE.





For further information please contact:


Sareum Holdings plc                                              01223 497700

Tim Mitchell, Chief Executive Officer
Buchanan Communications                                          020 7466 5000

Tim Anderson,  Mary-Jane Johnson
Grant Thornton Corporate Finance                                 0207 383 5100
Colin Aaronson, Philip Secrett



About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. The Company was formed in August 2003 to discover new drugs
for the treatment of cancer.  Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.



A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease.  Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression.  Knowledge of
the structure of the potential drugs and how they 'lock-in' to their target
protein assists greatly in the development of high-quality drug candidates.
Determining structure is a complex task and requires leading-edge equipment and
experienced staff.  Sareum's approach to structure determination utilises its
proprietary protein expression platform in order to produce multiple recombinant
proteins that accelerate structure determination using x-ray crystallography.



Once the structure is determined, the Company's innovative fragment screening
platform is used to identify novel chemical templates designed to interact with
the target protein.  Sareum then uses its high-throughput medicinal chemistry
platform to rapidly optimise these molecules and develop the most promising into
potential drug candidates.



Sareum aims to successfully deliver drug candidates for licensing to larger
pharmaceutical companies at the pre-clinical or early clinical trials stage.
This is funded by provision of its specialist drug discovery capabilities to
partners in the pharmaceutical and biotechnology industries.



Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR.  For further information, please visit
www.sareum.co.uk








                      This information is provided by RNS
            The company news service from the London Stock Exchange